BioTime Inc. (BTX)

2.30
AMEX : Health Technology
Prev Close 2.30
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.08 / 3.50
Avg Volume 406.00K
Exchange AMEX
Shares Outstanding 126.87M
Market Cap 291.81M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AgeX Announces NIH Grant Award

null

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADES, ALCO, ARTX, EVI, FNJN, INXN, KLXI, KODK, TGEN, XOXO Downgrades: BTX, CCRN, NFBK, WEB Initiations: METC Read on to get TheStreet Quant Ratings' detailed report:

BioTime Announces Cash Sale Of Ascendance Biotechnology

BioTime Announces Cash Sale Of Ascendance Biotechnology

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc.

BioTime Reports Fourth Quarter And Fiscal 2017 Results

BioTime Reports Fourth Quarter And Fiscal 2017 Results

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the fourth quarter and fiscal year ended December 31, 2017.

Commit To Buy BioTime At $2, Earn 14.4% Annualized Using Options

Commit To Buy BioTime At $2, Earn 14.4% Annualized Using Options

Investors considering a purchase of BioTime Inc stock, but cautious about paying the going market price of $2.69/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2 strike, which has a bid at the time of this writing of 15 cents.

BioTime Submits CE Mark Application For European Approval Of Renevia®

BioTime Submits CE Mark Application For European Approval Of Renevia®

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market...

BioTime Announces DSMB Approval To Proceed To Cohort 4 Of The OpRegen® Clinical Trial

BioTime Announces DSMB Approval To Proceed To Cohort 4 Of The OpRegen® Clinical Trial

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the...

BioTime To Announce Fourth Quarter And Fiscal 2017 Results On March 15, 2018

BioTime To Announce Fourth Quarter And Fiscal 2017 Results On March 15, 2018

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and...

AgeX Therapeutics CEO Dr. Michael D. West To Present At Three Conferences In March 2018

AgeX Therapeutics CEO Dr. Michael D. West To Present At Three Conferences In March 2018

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

BioTime To Present At The Raymond James 39th Annual Institutional Investor Conference

BioTime To Present At The Raymond James 39th Annual Institutional Investor Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of...

BioTime Announces Appointment Of Gary S. Hogge, DVM, MS, PhD, As Sr. Vice President, Clinical And Medical Affairs

BioTime Announces Appointment Of Gary S. Hogge, DVM, MS, PhD, As Sr. Vice President, Clinical And Medical Affairs

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Gary S.

BioTime Appoints Cavan Redmond To Its Board Of Directors

BioTime Appoints Cavan Redmond To Its Board Of Directors

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redmond as an independent...

Data From BioTime's OpRegen® And Vision Restoration Programs To Be Presented At ARVO 2018

Data From BioTime's OpRegen® And Vision Restoration Programs To Be Presented At ARVO 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have been accepted and will be...

BioTime To Participate At The BIO CEO And Investor Conference In New York, February 12th And 13th 2018

BioTime To Participate At The BIO CEO And Investor Conference In New York, February 12th And 13th 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer of...

Commit To Buy BioTime At $2, Earn 12% Annualized Using Options

Commit To Buy BioTime At $2, Earn 12% Annualized Using Options

Investors considering a purchase of BioTime Inc shares, but cautious about paying the going market price of $2.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2 strike, which has a bid at the time of this writing of 15 cents.

Renevia® Data From The Successful Pivotal Trial To Be Presented At The IMCAS Conference

Renevia® Data From The Successful Pivotal Trial To Be Presented At The IMCAS Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal...

BioTime To Present At The Noble Capital Markets 14th Annual Institutional Investor Conference In Fort Lauderdale, January 29, 2018

BioTime To Present At The Noble Capital Markets 14th Annual Institutional Investor Conference In Fort Lauderdale, January 29, 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will...

BioTime Announces Clinical And Corporate Milestone Targets For 2018

BioTime Announces Clinical And Corporate Milestone Targets For 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and corporate milestone targets.

BioTime Announces Issuance Of 41 New Patents To Expand And Bolster Its Patent Estate

BioTime Announces Issuance Of 41 New Patents To Expand And Bolster Its Patent Estate

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the issuance of 41 new patents over the past 12...

AgeX Therapeutics To Present At Biotech Showcase Annual Conference

AgeX Therapeutics To Present At Biotech Showcase Annual Conference

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

AgeX Therapeutics Identifies Genes Implicated In Tissue Regeneration And Cancer

AgeX Therapeutics Identifies Genes Implicated In Tissue Regeneration And Cancer

AgeX Therapeutics, Inc. ( AgeX), a subsidiary of BioTime, Inc.

BioTime To Participate In The LifeSci Advisors Corporate Access Event In San Francisco, January 8 - 10, 2018

BioTime To Participate In The LifeSci Advisors Corporate Access Event In San Francisco, January 8 - 10, 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and...

Additional Renevia Data From The Successful Pivotal Trial Was Presented At The IFATS Conference

Additional Renevia Data From The Successful Pivotal Trial Was Presented At The IFATS Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal...

Data From BioTime's Renevia® Program To Be Presented At IFATS Conference

Data From BioTime's Renevia® Program To Be Presented At IFATS Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal...

TheStreet Quant Rating: D (Sell)